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N eurogenic bowel dysfunction is a severely troubling entity for patients with neurological disease or injury. The complex symptom cluster presents a challenge, not only for the patients but also for the treating clinician. Without intervention, patients are bound to have a reduced quality of life, and experience social impacts and secondary complications that come along with it. A careful 
initial assessment provides an idea of symptom severity and is crucial for successful rehabilitation. The mainstay of treatment remains a 
conservative approach of managing faecal incontinence or optimising the mechanics of defecation to improve patient’s quality of life. This 
article attempts to provide a comprehensive review of existing literature on pathophysiology, assessment and management of neurogenic 
bowel dysfunction. 
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The term ‘neurogenic bowel’ encompasses the manifestations of bowel dysfunction resulting from 
sensory and/or motor disturbances1 due to central neurological disease or damage. Neurogenic 
bowel dysfunction (NBD) is a particularly common occurrence in patients with spinal cord injury 
(SCI), spina bifida and multiple sclerosis (MS) and has been found to worsen progressively in 
these conditions.2–4 Its main symptoms include constipation, faecal incontinence (FI),5 evacuation 
difficulties or a combination of these.4,6–8
The significant impact of NBD on patient’s life is evident from the number of patients reporting 
bowel symptoms. For instance, about 95% of SCI patients report constipation,5 75% report at least 
one episode of FI per year whereas 5% report a daily occurrence of incontinence. The prevalence 
of constipation and/or FI among MS patients ranges from 20% to 73%.9,10 A similar high occurrence 
of FI ranging from 30% to 50% has been reported in Parkinson’s disease (PD) patients. There is little 
doubt that NBD affects both the physical and psychological aspects of quality of life and its early 
recognition and management are vital.
Pathophysiology 
Damage to the spinal cord or brain can interrupt neural pathways. Location and severity of such 
damage are the key factors in determining colorectal function and the nature and extent of 
subsequent symptoms. However, it should be kept in mind that symptoms are not always easy to 
determine and can change with time. For instance, in MS there are often multiple lesions, which 
keep changing over time and in SCI the precise level of injury is often not clear during the early 
stages due to spinal shock, which can last up to 6 weeks. Moreover, the nervous system, being 
a complex entity, does not always present a fixed clinical pattern even in the same disease or 
trauma patterns. Broadly, neurogenic bowel symptoms are divided into two patterns depending 
upon the level of disease or injury being above or below the conus medullaris.
Supraconal disorder – ‘upper motor neuron bowel syndrome’ or 
‘hyperexic bowel’ 
This pattern is seen in patients who have disease/injury above the conus medullaris and involves 
loss of supraspinal inhibitory input resulting in hypertonia of colorectum. The increase in colonic 
wall, pelvic floor and anal tone results in reduced colonic compliance, overactive segmental 
peristalsis and underactive propulsive peristalsis.11–13 As the peristalsis and haustral movements 
become less effective the transit slows down throughout the colon.14–16 The spastic constricted 
state of the external anal sphincter (EAS) worsens the situation further by causing retention of 
stool. The combination of these physiological responses to supraconal injury makes constipation 
a dominant gut symptom. 
Infraconal disorder – ‘lower motor neuron type’ or ‘areexic bowel’ 
Infraconal lesions are a consequence of disruption of autonomic motor nerves due to damage 
to parasympathetic cell bodies in the conus medullaris or their axons in the cauda equina. This 
is characterised by loss of colorectal tone and attenuated rectoanal inhibitory reflex, resulting 
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in a cyclical pattern of insensate rectal filling and progressive rectal 
distension eventually leading to FI.5 Furthermore, the incontinence is not 
helped by a reduction in resting and squeeze pressure due to flaccid 
anal sphincters and laxity of pelvic floor muscles which allows excessive 
descent of pelvic contents reducing the anorectal angle and opening the 
rectal lumen.13 
Clinical features
NBD is known to restrict everyday activities and limits patients even 
further, making them feel isolated and housebound.17 Both ends of the 
spectrum; constipation and FI can be present in the affected patient. 
Constipation causes significant distress, especially due to its associated 
symptoms of abdominal bloating, pain and nausea. Impaction with 
compromised respiratory function as in high-level SCI can even lead to 
difficulty in breathing caused by reduced diaphragmatic excursion.Chronic 
constipation can also lead to rectal prolapse, which can lead to a feeling 
of incomplete evacuation or incontinence, depending upon the severity. 
The other resultant products of constipation are haemorrhoids and anal 
fissure. While haemorrhoids usually cause chronic blood loss and perianal 
itchiness, they can also cause pain similar to anal fissure. The pain from 
either of these conditions can be severe enough to trigger autonomic 
dysreflexia in susceptible patients. Autonomic dysreflexia is a medical 
emergency, as it can lead to potentially life-threatening hypertension in 
individuals with SCI above the sixth thoracic vertebrae. Its cardinal sign 
is rapidly developing severe headache but other signs such as flushing, 
sweating and blotchiness above the lesion are also commonly observed. 
Acute autonomic dysreflexia should be treated with sublingual nifedipine 
or a glycerine trinitrate patch or spray to control blood pressure.
At the other extreme is FI, which presents its own challenges. It usually 
leads to social and hygiene problems, skin breakdown and an increase in 
urinary tract infections. It is known to be one of the symptoms that most 
seriously affects quality of life in SCI patients18 as it can have a profound 
effect on a patient’s physical, psychological, social and sexual function.19 
 
Assessment
Symptom assessment depends on identifying any alarm symptoms 
that may signify sinister gut pathology, and also identifying what 
bowel function was like prior to the onset of NBD symptoms. Clinical 
assessment with a bowel diary can help clarify day-to-day experience, 
as well as potentially identifying trigger factors to symptoms. The bowel 
diary should include details such as number of bowel movements 
per day, stool consistency, straining during bowel movements and 
presence of abdominal pain or bloating. The Bristol stool scale can also 
be used separately to document stool consistency accurately in order 
to formulate an appropriate management plan. Key current symptoms 
to note when taking a history are shown in Table 1.20
A neurological examination can reveal the severity of injury to the 
nervous system and the completeness of injury. The abdomen 
should be inspected for distention. A full physical examination should 
include rectal examination, which can provide an insight to volitional 
contraction due to the EAS and the patient’s ability to produce voluntary 
contraction of the puborectalis muscles in addition to providing useful 
info about the presence of haemorrhoids or masses.21 It is vital to 
establish whether an individual has hyperreflexic or areflexic bowel 
to help tailor the management accordingly. The clinical signs that 
can help differentiate between the two conditions are presented in 
Table 2.  
Patients with NBD, in addition to having changes in bowel motility and 
sphincter control, can also suffer from impaired mobility and hand 
dexterity, due to coexisting central nervous system pathology.2 Thus, the 
strength of the upper and lower extremities of the patient should also 
be assessed; their sitting balance and ability to transfer; length of the 
patient’s arms, legs and trunk, and the patient’s weight. Such thorough 
examination will provide an insight to determine whether the patient can 
perform daily tasks, including bowel management, or whether assistance 
would be needed. 
In addition to the clinical examination, diagnostic tests can be very 
useful for the clinicians. For instance, an abdominal X-ray can be helpful 
in confirming and quantifying faecal retention and megacolon. An 
endoanal ultrasound can identify an external or internal anal sphincter 
defect and a barium enema or magnetic resonance (MR) proctogram 
can diagnose paradoxical sphincter contractions. Such prior knowledge 
can help the clinician formulate an appropriate management plan 
tailored to an individual’s requirements. Anorectal physiology studies 
can help obtain information on anorectal sensations. However, a digital 
rectal examination to assess the sphincter contractile strength and 
pinprick assessment of perineal sensitivity can obviate the need for 
formal anorectal physiology studies in most cases. Similarly, transit 
measurement is not needed for most patients – the quantification of 
urge frequency provides the necessary information (urge that is daily 
or less often usually signifies slow transit).
Management 
Bowel management in neurogenic gut dysfunction requires the 
provision of interventions tailored to an individual’s needs in order to 
establish a scheduled and effective bowel evacuation and to prevent 
Table 1: Key symptoms to note during initial patient 
assessment
Pre-injury bowel habit
Frequency of urge to void rectum
Bowel opening frequency
Time spent per bowel episode
Episodes of urge faecal incontinence
Episodes of passive faecal incontinence
Meal frequency and content
Previous medical history
Current and past medication
Levels of activity – general mobility, exercise
Communication and cognitive ability
Psychological and emotional factors
Home and care circumstances
Table 2: Bedside signs to differentiate supraconal and 
infraconal disorders
Supraconal disorder  
(hyperreflexic bowel)
Infraconal disorder  
(areflexic bowel)
High resting anal tone No/low resting anal tone
Anal reflex present – reflex contraction of 
anus in response to stroking of anal skin
Anal reflex absent
Bulbocavernosus reflex present – reflex anal 
contraction on squeezing glans penis/clitoris
Bulbocavernosus reflex absent
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the associated morbidity. Individuals with hyperreflexic bowel have an 
intact reflex arc between the spinal cord and colon/anorectum and, as 
such, the stimulation of the rectum (chemically or mechanically) results 
in evacuation of stool. On the other hand, individuals with areflexic 
bowel require gentle Valsalva manoeuvres and/or manual evacuation. 
The aim is to attain a soft stool consistency in hyperreflexic bowel to 
help easy evacuation and firm-formed stool in areflexic bowel to avoid 
incontinence episodes. Ironically, despite NBD being a common entity, 
very little research has been done in this field according to a recent 
Cochrane review.22 Moreover, the evidence that is available is of low 
methodological quality as per the authors. 
The severity of NBD is inversely related to quality of life. Coggrave et al. 
found that the impact of NBD in SCI patients was significantly greater than 
other aspects of the disorder.23 Several therapeutic approaches exist for 
the management of neurogenic bowel and although isolated strategies 
may act as a starting point, more often than not the management is 
multi-dimensional, involving different treatment modalities. A step-wise 
approach to managing NBD is shown in Figure 1. 
Dietary patterns and lifestyle alteration
Changing diet to include high fibre content is usually recommended as 
a first step in the bowel management programme. A systematic review 
looking at non-neurogenic chronic idiopathic constipation concluded 
that, although few studies have shown the benefit of using soluble fibre 
in this patient group, the evidence for using insoluble fibre is conflicting.25 
Similar results were reported by Markland et al. in their review of more 
than 10,000 adults, where they found a beneficial effect of increasing 
fluid intake but not of fibre or exercise in managing constipation.26 
Looking specifically at individuals with NBD, a case series of 11 SCI 
patients reported an increase, rather than decrease in colonic transit 
time with the use of insoluble fibre.27 However, the subjects received a 
very high-fibre diet without proper advice on fluid intake and as such 
the results are not thought to be relevant to clinical practice. As the 
insoluble fibre can help bulk and soften the stool, a sensible approach 
is to adjust its intake according to the stool consistency. 
Similar to diet, there is no unanimous opinion about the effects of 
increased physical activity in managing constipation, as there are a few 
studies in favour of it28–30 and a few against it.26,31–33 To our knowledge, 
there has been no study looking at its efficacy in individuals with NBD.
Despite an absence of strong evidence base for these conservative 
interventions, they have been found to be useful in neurogenic bowel 
patients.14 We support the aim of establishing a pattern of scheduled 
defecation and exhausting the conservative interventions of dietary 
and lifestyle modification before moving on to pharmacological 
interventions. A successful bowel regime will usually be based around 
the individual’s activities and routine, besides taking into account 
the locally available expertise and resources. In general, scheduled 
defecation should be attempted once a day or on alternate days. 
However, it is vital to set the frequency of a bowel programme according 
to the bowel habits of an individual prior to the injury. For instance, 
setting up a daily bowel regime for an individual who only ever opened 
their bowel twice a week prior to spinal injury is simply not going to be 
successful. Another point to consider while setting the regime is that 
the bowel contractions are maximal on waking up and after a meal or 
warm drink (gastrocolic reflex). Although there is no strong evidence for 
its use in NBD,34,35 patients are still advised to make use of gastrocolic 
reflex by eating or drinking 15–30 minutes before attempting to empty 
their bowels.36 
Abdominal massage
Abdominal massage has been used as a treatment for chronic 
constipation since late 1800s as there was a belief that it stimulates 
peristalsis.37 Over the years it fell into disuse, but with growing evidence 
it has started regaining its popularity and it has reportedly been used by 
22–30% of NBD patients.38,39 
In a study of 24 SCI patients, abdominal massage added to the standard 
bowel programme led to a significant reduction in colonic transit time 
(90.60 ± 32.67 hours versus 72 ± 34.10 hours, p=0.035), abdominal 
distension (45.8% versus 12.5%, p=0.008) and FI (41.7% versus 16.7%, 
p=0.031), while increasing the frequency of defecation (4.61 ± 2.17 
versus 3.79 ± 2.15, p=0.006).40 Another study by Albers et al. on 
seven patients with paraplegia secondary to SCI also found beneficial 
effects of this technique.41 McClung et al., in their study on 30 patients 
with MS and constipation, found an increase in the frequency of 
defecation in patients who were taught how to perform abdominal 
massage as compared to the control group, who were given only bowel 
management advice.42 A randomised controlled trial involving patients 
who suffered cerebrovascular accident reported a reduction in severity 
of constipation and increased defecation frequency in the group 
receiving abdominal massage.43
 
Despite the evidence showing this to be an effective technique, its 
mechanism of action is not entirely clear. Several theories have been 
proposed, including activation of intestinal stretch receptors, which 
causes an increase in intestinal and rectal contraction,44 elicitation of 
measurable waves of rectal muscle contraction,45 decrease in colonic 
transit time,40 stimulating the parasympathetic nervous system, thereby 
leading to increase in gut secretions and motility and relaxing sphincters 
in the digestive tract.46 Whatever the mechanism, abdominal massage 
has a clear advantage of being inexpensive, non-invasive and risk-free. 
Oral laxatives
Oral laxatives are the next step up the ladder in the management of 
NBD. High-quality data exist in the form of several randomised controlled 
trials (RCTs) confirming the beneficial effect of laxatives in individuals 
with NBD. Polyethylene glycol (PEG/Macrogol) has been found to be 
superior to lactulose in two RCTs,47,48 leading to higher bowel frequency 
in both studies (p<0.01 in the first and p<0.002 in the second study). 
Other commonly used laxatives include bisacodyl and senna (colonic 
stimulants), docusate (stool softener) and fybogel (bulk forming). While 
osmotic and stimulant laxatives form the mainstay of treatment, several 
Reproduced with permission from Nature Publishing Group; Consensus review of best 
practice of transanal irrigation in adults24
Figure 1: Step-wise approach to treatment of bowel 
dysfunction
Stoma
Sacral anterior
root stimulation
Antegrade colonic irrigation
Sacral nerve stimulation
Transanal irrigation
Digital stimulation / suppositories / biofeedback
Diet and uid / lifestyle alteration / laxatives or constipating drugs
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other drugs with different mechanisms of action have shown promising 
results. Cisapride is one such drug which acts as 5-HT4 receptor agonist 
and, although it was reported to reduce colonic transit time in SCI49 and 
PD patients,50 it has almost fallen into disuse due to its adverse cardiac 
effects. A newer 5-HT4 receptor agonist, prucalopride has shown 
an improvement in frequency of bowel movements per week and a 
significant reduction in colonic transit time in SCI patients.51
Neostigmine, a prokinetic, mediates bowel emptying via an increase in 
parasympathetic stimulation of the gut, thereby leading to an increase 
in peristalsis. An RCT of 13 SCI patients found an improved stool 
expulsion52 and a double-blind crossover trial of seven SCI patients 
reported a reduction in bowel evacuation time.53 Its adverse effects of 
bradycardia and bronchoconstriction are well known and limit its use 
to hospital settings.52 
Other drugs, such as lubiprostone, a chloride channel activator, and 
linaclotide, a guanylate cyclase C receptor agonist, cause an increase 
in fluid secretion into the gut. They have shown some promising results 
but need further studies to confirm their efficacy in individuals with NBD. 
Digital anal stimulation, suppositories and enemas
Digital stimulation is a well-established technique used in individuals 
with NBD to help facilitate bowel evacuation. The technique requires 
the patient or the carer to insert a gloved, lubricated finger into the 
rectum and move it in a rotatory pattern. It works by dilating the anal 
canal and relaxing the puborectalis muscle, which leads to a reduction 
in the anorectal angle. Both of these essentially lead to a reduction in 
resistance to the passage of stool, thereby assisting bowel emptying.
 
Shafik et al. in their study on 11 patients, noted left colonic contractions 
upon rectal distension which were absent after anaesthetising the rectum 
and anal canal. They named this the recto-colic reflex.54 This rectocolic 
reflex has been found to be useful in initiating bowel movement in 
individuals with supraconal disorders but not in those with infraconal 
lesions. Another study on 18 healthy subjects and nine SCI patients found 
an increase in the rectal pressure in both groups with anal dilatation.55 
A case series of six SCI patients by Korsten et al. reported an increase in 
the frequency of peristaltic waves during digital rectal stimulation (DRS) 
and in the period immediately after cessation of DRS. This increase in 
peristalsis was accompanied by expulsion of barium oatmeal, thereby 
providing evidence for increased left-sided colonic motility.56 
Overall, DRS is a safe and effective intervention, with the only 
precaution advised to be gentle to avoid rectal mucosa injuries57 and 
to avoid precipitation of autonomic dysreflexia.58 If DRS is not helpful 
in providing the desired symptomatic relief, it is augmented by the 
use of suppositories and enemas, which are preferred over manual 
evacuation of the stool. Glycerine and bisacodyl are the commonly used 
suppositories, with the latter having either hydrogenated vegetable oil 
or PEG as a base. Three studies (one good-quality RCT) have reported 
better results with PEG-based suppositories.59–61 Sodium bicarbonate 
suppositories (Lecicarbon E) release carbon dioxide, which subsequently 
stimulates the rectal reflex activity are also commonly used. A clinically 
significant decrease was noted in the amount of nursing time with the 
use of these suppositories in addition to less requirement for assistance 
and a reduction in time spent on bowel care. Enemas have been used 
in the event of suppositories not being helpful. Docusate mini enema 
has been shown to be more effective in NBD than glycerine or bisacodyl 
suppositories.59 The other enemas commonly used are sodium citrate 
and sorbitol microenemas (Micralax®). Large volume phosphate enemas 
are not routinely used due to difficulty with retention and the risk of 
triggering autonomic dysreflexia. 
Anal plugs
Anal plugs are disposable devices made of porous foam, which expands 
rapidly when placed in anal canal, thereby closing the anus. They come 
in two sizes and the patients are usually given both sizes in order for 
them to find the size that gives better symptomatic control. Although 
there have been RCTs looking at their effectiveness, none of these have 
been in the neurogenic patients.62 The side effects noted in different 
studies include continuing stool leakage, plug loss and local irritation, the 
latter being uncommon in neurogenic patients. They are quite effective 
in preventing leakage of stool or gas, as long as it is a small amount. 
A recent systematic review found that, although there are limited data 
available regarding their beneficial outcomes, plugs may be helpful 
in reducing incontinence and its associated problems, provided that 
patients tolerate and persist with their use.63 
Antegrade continence enema 
Malone and colleagues are renowned for developing this technique of 
antegrade irrigation of bowel via an appendicostomy, which acts as a 
conduit for instillation of tap water or osmotic agent.64 A valve mechanism 
prevents leakage of stool through it, while allowing for catheterisation. 
Caecostomy can be used for patients who had previously undergone 
appendicectomy. It was initially used in the paediatric population65 but 
over time it gained popularity among adults, in whom a satisfaction rate 
of over 80% has been reported at a mean follow-up of 75 months.66 
The evidence for its efficacy is limited to only a few retrospective 
studies in the adult population, but a finding in all these studies is of 
high satisfaction rates and improvement in quality of life post antegrade 
continence enema (ACE) procedure in patients with neurogenic bowel 
(see Table 3). The complications reported with ACE include stenosis, 
leakage or failure to effectively treat symptoms, thereby requiring a 
redo surgery. The rate of conversion to a stoma has been reported to be 
around 30%.67
An alternative to ACE is percutaneous endoscopic colostomy (PEC), in 
which an enterostomy tube is endoscopically placed in the left colon 
and acts as an irrigation port. A study of 27 patients undergoing PEC 
reported symptomatic improvement in 80% of subjects undergoing 
the procedure.74
Transanal irrigation 
Transanal irrigation (TAI) involves introducing water into the colon via 
the anus, with the aim of aiding evacuation of contents from the rectum 
and left-sided colon. Although TAI has been practised since 1500 BC, it 
Table 3: Antegrade continence enema in adult population
Study Methods Main outcomes
Basson et al.68 n=111 (7 neuropathic) Improvement in 100% of 
neuropathic patients
Myers et al.69 n=15 (15 neuropathic) Improvement in 80% of patients
Imai et al.70 n=21 (21 spina bifida) Improvement in 90% of patients
Teichman et al.71 n=7 (3 spinal cord injury) Improvement in 75% of patients 
and quality of life
Christensen  
et al.72 
n=8 (8 spinal cord injury) Improvement in 87% of patients 
and quality of life
Teichman et al.73 n=7 (4 spinal cord injury) Improvement in 100% of patients
Emmanuel_FINAL.indd   112 09/12/2016   13:06
113EUROPEAN NEUROLOGICAL REVIEW
Evaluation and Treatment of Neurogenic Bowel Dysfunction 
is Shandling and Gilmour who introduced it into modern medicine after 
using it to achieve faecal continence in children with spina bifida.75 
Several commercial devices are available with a different design but, for 
the purpose of this paper, we have used TAI as the broad term (Figure 2). 
The use of TAI for the treatment of NBD was established by Christensen et 
al. in 2006.76 In their randomised controlled study of 87 SCI patients with 
NBD, they compared the use of TAI to conservative bowel management, 
for a 10-week trial period and found TAI to be superior. The results are 
summarised in Table 4.
TAI has also been found to be helpful in neurological disease beyond 
those affecting the spinal cord. Our group has previously reported an 
improvement of over 50% in constipation and FI score in 30 MS patients, 
post-TAI use, who failed to respond to maximal medical treatment for 
bowel dysfunction.77 In individuals experiencing NBD secondary to PD, 
TAI has been shown to reduce constipation symptoms.78 Not all patients 
will respond favourably to this treatment. Few predictive factors which 
have been identified as relating to a successful outcome include low 
rectal volume at urge to defecate, low maximal rectal capacity, male 
gender, mixed constipation and FI symptoms, and prolonged colonic 
transit time.78
The absolute contraindications include anal stenosis, recent rectal 
surgery, active inflammatory bowel disease, active diverticulitis, colorectal 
cancer and ischaemic colitis.95,96 The main complication associated with 
TAI is bowel perforation. However, the rates for this are pretty low, with 
an estimated risk of irrigation-induced perforation to be one per 50,000 
(0.0002%).79 Importantly, this risk is not thought to be cumulative, with the 
greatest rates of damage occurring early on, especially in poorly selected 
patients who have not been appropriately trained.97 
Electrical stimulation therapies 
Sacral anterior nerve root stimulation 
This implantation of sacral anterior nerve root stimulator (SARS) 
was first reported in 1982 by Brindley et al. and it was developed to 
control urological symptoms in SCI patients.80 It consists of an implant 
placed via a laminectomy of L4 to S2. The anterior roots of S2 to S4 
are placed within the stimulator and connected to a receiver block, 
which is controlled by a wireless device.81 Although it primarily acts on 
the bladder, by triggering micturition, suppressing detrusor overactivity 
and detrusor sphincter dyssynergia,82 it is also known to stimulate 
peristalsis in the distal colon and rectum, thereby increasing the 
frequency of defecation.83–85 
Binnie et al. reported a significant increase in defecation in SCI patients 
implanted with SARS.84 Furthermore, an improvement in bowel function 
in the ability to evacuate spontaneously, reduced requirement of manual 
help for defecation and an improved quality of life have also been 
reported.85,86 The utility of SARS as a treatment option for managing 
bladder dysfunction has been well proven but evidence of its efficacy 
in managing bowel function is still scarce. A recent systematic review by 
Worsoe et al. identified only 14 papers that studied use of SARS for bowel 
dysfunction. They reported that the endpoints varied between studies 
and in some there was a lack of well-defined endpoints.87 
Sacral neuromodulation 
Similar to SARS, sacral nerve stimulation (SNS) was also developed for 
controlling urological symptoms. It took more than a decade for it to 
be adapted for bowel dysfunction, with the first reported implant for FI 
taking place in 1995. It is a two-staged procedure, with the first stage 
being a trial period of 2-4 weeks, during which a stimulating electrode is 
placed onto the anterior sacral roots of S2 or S3 via sacral foramina and 
connected to an external stimulator. If the patient has a satisfactory 
response, they proceed to the second stage, where a permanent 
electrode and a pulse generator are implanted. 
Although mode of action of SNS is not completely understood, it 
has been proposed that it controls FI by stimulating the somatic and 
autonomic nervous system.88 A few studies have also proposed that 
it has an effect on the central nervous system.89,90,107,108 Its effect in 
cases of constipation has been suggested to be due to an increased 
frequency of antegrade pressure sequences and high-amplitude 
pressure sequences. Its role in neurogenic patients has been evaluated 
by few studies. While Schurch et al. reported no improvement in 
patient symptoms post SNS in complete SCI patients,91 several studies 
have shown a positive clinical outcome of SNS for patients with 
incomplete SCI. Jarret et al. studied 13 patients with spinal insults 
(disc prolapse, trauma, spinal stenosis and post-surgery) and reported 
a decrease in the mean number of incontinence episodes from 9.33 
(standard deviation [SD] 7.64) at baseline to 2.39 (SD 3.69) (p=0.012) 
at 12 months follow-up. They also reported a significant improvement 
(p=0.022) in the ability to defer defecation post SNS.92 Another study 
of 29 patients having neurogenic FI reported marked improvement 
or complete recovery of continence in 28 patients after a median 
follow-up of 35 months (range 3–71 months) post SNS. Additionally, 
there was an improvement noted in quality of life.93 Patients with 
cauda equina syndrome having flaccid paresis of anal sphincters 
also achieved an improvement in continence after SNS.94 Lombardi 
Figure 2: PeristeenTM anal irrigation system
Table 4: Results of randomised controlled trial comparing 
transanal irrigation to conservative bowel management
Scoring system Transanal 
irrigation
Mean (SD)
Cons bowel 
management
Mean (SD)
p-value
Cleveland constipation score (0–30; 
30=severe symptoms)
10.3 (4.4) 13.2 (3.4) 0.0016
St Mark’s faecal incontinence score 
(0–24; 24=totally incontinent)
5.0 (4.6) 7.3 (4.0) 0.015
Neurogenic bowel dysfunction score 
(0–47; 14+=severe bowel dysfunction)
10.4 (6.8) 13.3 (6.4) 0.048
SD = standard deviation
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et al., in their study of 29 individuals with NBD (12 with constipation, 
11 with FI) reported a significant improvement in Wexner constipation 
score (p=<0.05) and in Wexner FI score (p=<0.018). 
Tibial nerve stimulation 
Stimulation of the tibial nerve can be done using surface electrodes 
(transcutaneous tibial nerve stimulation; TTNS) or needle electrode 
(percutaneous tibial nerve stimulation; PTNS). Several studies have 
reported its efficacy in managing FI in non-neurogenic patients but 
the evidence for its use in NBD is almost non-existent. Mentes et al. 
reported improvement in the Wexner incontinence score in two SCI 
patients post PTNS.95 An RCT by Leroi et al. included neurogenic patients, 
while comparing TTNS with sham stimulation. Although no specific data 
or analysis were presented specifically for neurogenic patients, it did 
not report a significant improvement in the number of FI episodes or 
anorectal physiology.96 
 
Colostomy/Ileostomy
Stoma formation is usually reserved as a last resort for managing NBD 
once all other medical treatments have been exhausted. Studies have 
shown that stoma helps reduce bowel management time,97–100 provides 
independence,98–99 reduces the number of hospitalisations100 and 
improves quality of life in neurogenic patients.97,100 Moreover, satisfaction 
rates were found to be high among patients, the majority of whom would 
have preferred to have the procedure done earlier.97 Randell et al. in their 
study of 52 SCI patients concluded that neurogenic patients with stoma 
were no worse off than those without, in regard to their general well-
being and quality of life.101 
While choosing colostomy for their patients, physicians need to 
remember that stoma in neurogenic patients carries more complications 
than in other patients.102 Another significant point to remember is that, 
although stomas can be quite effective in reducing the time spent on 
bowel care and controlling FI, they do not correct the colonic transit time 
and as such, there might be a continual requirement for stoma irrigation 
or laxative use. 
Summary
A stepwise approach to bowel management, based on a systematic 
assessment is effective in managing the intrusive gut symptoms 
that afflict the majority of patients with central neurological disease. 
Conservative therapy is effective in most patients, with only a minority 
needing to be considered for as yet not fully proven neuromodulatory 
therapies or invasive surgical ones. q
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